CN218214665U - Lead can and transport container - Google Patents
Lead can and transport container Download PDFInfo
- Publication number
- CN218214665U CN218214665U CN202222451405.XU CN202222451405U CN218214665U CN 218214665 U CN218214665 U CN 218214665U CN 202222451405 U CN202222451405 U CN 202222451405U CN 218214665 U CN218214665 U CN 218214665U
- Authority
- CN
- China
- Prior art keywords
- lead
- side wall
- cover
- axis
- tank
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229940121896 radiopharmaceutical Drugs 0.000 claims abstract description 21
- 239000012217 radiopharmaceutical Substances 0.000 claims abstract description 21
- 230000002799 radiopharmaceutical effect Effects 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims description 33
- 229910052751 metal Inorganic materials 0.000 claims description 29
- 239000002184 metal Substances 0.000 claims description 29
- 239000011241 protective layer Substances 0.000 claims description 12
- 238000007789 sealing Methods 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 8
- 229920001169 thermoplastic Polymers 0.000 claims description 8
- 239000004416 thermosoftening plastic Substances 0.000 claims description 8
- 229910001245 Sb alloy Inorganic materials 0.000 claims description 7
- 239000002140 antimony alloy Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 238000005260 corrosion Methods 0.000 claims description 4
- 239000002519 antifouling agent Substances 0.000 claims description 3
- 230000007797 corrosion Effects 0.000 claims 1
- 230000032258 transport Effects 0.000 description 26
- 239000010410 layer Substances 0.000 description 15
- 230000002285 radioactive effect Effects 0.000 description 14
- 238000010586 diagram Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000005855 radiation Effects 0.000 description 6
- 230000004308 accommodation Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229920001971 elastomer Polymers 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 239000002250 absorbent Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 3
- 229940090044 injection Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229910052765 Lutetium Inorganic materials 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 208000017055 digestive system neuroendocrine neoplasm Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 2
- 229940066939 octreotide injection Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 239000012857 radioactive material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- MXDPZUIOZWKRAA-PRDSJKGBSA-K 2-[4-[2-[[(2r)-1-[[(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-4-[[(1s,2r)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-y Chemical compound [177Lu+3].C([C@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC1=O)C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1)C1=CC=CC=C1 MXDPZUIOZWKRAA-PRDSJKGBSA-K 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- AUBLVGBHEQEQOF-UHFFFAOYSA-N O=[Lu] Chemical compound O=[Lu] AUBLVGBHEQEQOF-UHFFFAOYSA-N 0.000 description 1
- 108050001286 Somatostatin Receptor Proteins 0.000 description 1
- 102000011096 Somatostatin receptor Human genes 0.000 description 1
- 231100000987 absorbed dose Toxicity 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005255 beta decay Effects 0.000 description 1
- 230000005250 beta ray Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006261 foam material Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009049 secondary transport Effects 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 239000005028 tinplate Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Images
Landscapes
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
一种铅罐及运输容器,用于放射性药物的运输,所述铅罐包括:铅罐本体,所述铅罐本体内设置有敞口的容置槽,所述容置槽包括依次远离所述容置槽底部且依次邻接的第一容置空间以及第二容置空间;以及铅罐盖体,所述铅罐盖体具有凹槽,当所述铅罐盖体扣合在所述铅罐本体上时,所述容置槽与所述凹槽组成容纳部,所述铅罐盖体的侧壁的至少一部分容置在所述第二容置空间中,所述铅罐本体的侧壁的最大厚度小于所述铅罐盖体的侧壁的最大厚度。
A lead tank and a transport container, used for the transport of radiopharmaceuticals, the lead tank includes: a lead tank body, an open accommodating tank is arranged inside the lead tank body, and the accommodating tank includes The first accommodating space and the second accommodating space adjacent to the bottom of the accommodating tank in sequence; When on the main body, the accommodating groove and the groove form an accommodating part, at least a part of the side wall of the lead can lid is accommodated in the second accommodating space, and the side wall of the lead can body The maximum thickness is less than the maximum thickness of the side wall of the lead can lid.
Description
技术领域technical field
本公开涉及医药技术领域,尤其涉及一种铅罐及运输容器,用于运输放射性药物。The present disclosure relates to the technical field of medicine, in particular to a lead tank and a transport container for transporting radiopharmaceuticals.
背景技术Background technique
一些放射性药物含有的放射性核素的半衰期较短,由此导致放射性药物的有效期较短,例如,177Lu核素半衰期只有6.64天,177Lu核素标记的镥氧奥曲肽注射液的有效期仅为3天。该些放射性药物通常需要航空运输的方式进行运输配送,其运输容器需要满足放射性防护要求以及航空运输要求,现有的放射性药物的运输容器体积较大、重量较重,运输容器的制造成本以及运输成本均较高。The half-life of the radionuclide contained in some radiopharmaceuticals is short, which leads to a short period of validity of radiopharmaceuticals. For example, the half-life of 177 Lu nuclide is only 6.64 days, and the validity period of lutetium oxygen octreotide injection labeled with 177 Lu nuclide is only 3 sky. These radiopharmaceuticals usually need to be transported and distributed by air transport, and their transport containers need to meet the requirements of radioactive protection and air transport. The existing radiopharmaceutical transport containers are large in size and heavy in weight. The manufacturing cost of the transport container and the transportation The cost is higher.
实用新型内容Utility model content
本公开一些实施例提供一种铅罐,用于放射性药物的运输,其特征在于,所述铅罐包括:Some embodiments of the present disclosure provide a lead tank for transporting radiopharmaceuticals, wherein the lead tank includes:
铅罐本体,所述铅罐本体内设置有敞口的容置槽,所述容置槽包括依次远离所述容置槽底部且依次邻接的第一容置空间以及第二容置空间;以及The lead can body, the lead can body is provided with an open accommodating groove, and the accommodating groove includes a first accommodating space and a second accommodating space which are successively away from the bottom of the accommodating tank and successively adjacent to each other; and
铅罐盖体,所述铅罐盖体具有凹槽,a lead can lid, the lead can lid has a groove,
当所述铅罐盖体扣合在所述铅罐本体上时,所述容置槽与所述凹槽组成容纳部,所述铅罐盖体的侧壁的至少一部分容置在所述第二容置空间中,所述铅罐本体的侧壁的最大厚度小于所述铅罐盖体的侧壁的最大厚度。When the lead can lid is fastened on the lead can body, the accommodating groove and the groove form a receiving portion, and at least a part of the side wall of the lead can lid is accommodated in the first In the second accommodating space, the maximum thickness of the side wall of the lead container body is smaller than the maximum thickness of the side wall of the lead container cover.
在一些实施例中,在所述铅罐本体的轴线的方向上,所述第二容置空间的内侧壁随着逐渐靠近所述第一容置空间逐渐朝向所述铅罐本体的轴线收敛,In some embodiments, in the direction of the axis of the lead can body, the inner sidewall of the second accommodating space gradually converges toward the axis of the lead can body as it gradually approaches the first accommodating space,
所述铅罐盖体的侧壁的外表面包括第一外表面,在所述铅罐盖体的轴线的方向上,所述第一外表面随着逐渐远离所述铅罐盖体顶面逐渐朝向所述铅罐盖体的轴线收敛,The outer surface of the side wall of the lead can lid includes a first outer surface, and in the direction of the axis of the lead can lid, the first outer surface gradually moves away from the top surface of the lead can lid. converges towards the axis of the lead jar lid,
当所述铅罐盖体扣合在所述铅罐本体上时,所述第一外表面与所述第二容置空间的内侧壁匹配贴合使得铅罐本体的轴线与所述铅罐盖体的轴线共线。When the lead can body is fastened on the lead can body, the first outer surface is matched with the inner wall of the second accommodating space so that the axis of the lead can body is aligned with the lead can lid The axes of the body are collinear.
在一些实施例中,所述铅罐盖体的侧壁的内表面与所述第一外表面相交处具有圆角。In some embodiments, the intersection of the inner surface of the side wall of the lead can lid and the first outer surface has rounded corners.
在一些实施例中,所述铅罐盖体的侧壁的内表面平行于所述铅罐盖体的轴线,所述第一容置空间的内侧壁平行于所述铅罐本体的轴线,In some embodiments, the inner surface of the side wall of the lead can lid is parallel to the axis of the lead can lid, the inner wall of the first accommodating space is parallel to the axis of the lead can body,
当所述铅罐盖体扣合在所述铅罐本体上时,所述铅罐盖体的侧壁的内表面相对于所述第一容置空间的内侧壁更加靠近所述铅罐本体的轴线。When the lead can lid is fastened on the lead can body, the inner surface of the side wall of the lead can lid is closer to the inner surface of the lead can body than the inner side wall of the first accommodating space. axis.
在一些实施例中,所述铅罐盖体的侧壁的外表面还包括第二外表面和第三外表面,所述第三外表面位于所述第二外表面与第一外表面之间,In some embodiments, the outer surface of the side wall of the lead can lid further includes a second outer surface and a third outer surface, and the third outer surface is located between the second outer surface and the first outer surface ,
当所述铅罐盖体扣合在所述铅罐本体上时,所述第二外表面与所述铅罐本体的外侧壁共面,所述第三外表面与所述铅罐本体的侧壁顶面匹配贴合。When the lead can lid is fastened on the lead can body, the second outer surface is coplanar with the outer side wall of the lead can body, and the third outer surface is coplanar with the side wall of the lead can body. Matching fit on top of wall.
在一些实施例中,所述铅罐的材质为铅锑合金使得所述铅罐可以采用冲压方式制造。In some embodiments, the material of the lead can is lead antimony alloy so that the lead can can be manufactured by stamping.
在一些实施例中,所述铅罐的外表面涂覆有防护漆。In some embodiments, the outer surface of the lead can is coated with a protective paint.
在一些实施例中,所述铅罐的材质为铅锑合金。In some embodiments, the lead can is made of lead-antimony alloy.
本公开一些实施例提供一种放射性药物的运输容器,包括:Some embodiments of the present disclosure provide a transport container for radiopharmaceuticals, comprising:
药瓶,配置为容置放射性药物;a vial configured to hold a radiopharmaceutical;
前述实施例所述的铅罐,配置为容置所述药瓶;The lead container described in the foregoing embodiments is configured to accommodate the medicine bottle;
吸液海绵,配置为包裹所述铅罐,以吸收外泄液体;a liquid-absorbing sponge configured to wrap the lead tank to absorb spilled liquid;
金属密封罐,配置为容置由所述吸液海绵包裹的所述铅罐;a metal airtight tank configured to accommodate the lead tank wrapped by the liquid-absorbent sponge;
缓冲保护层,配置为包裹所述金属密封罐;以及a cushioning protective layer configured to wrap the metal canister; and
瓦楞纸箱,配置为容置由所述缓冲保护层包裹的所述金属密封罐,a corrugated box configured to house said metal sealed can surrounded by said cushioning protective layer,
其中,容置药瓶后的铅罐的表面进行热塑封使得所述铅罐外表面包裹热塑密封膜。Wherein, the surface of the lead tank containing the medicine bottle is thermoplastically sealed so that the outer surface of the lead tank is wrapped with a thermoplastic sealing film.
在一些实施例中,所述金属密封罐的材料为防腐蚀材料。In some embodiments, the material of the metal airtight tank is an anti-corrosion material.
附图说明Description of drawings
为了更清楚地说明本公开实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作一简单地介绍,显而易见地,下面描述中的附图是本公开的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。In order to more clearly illustrate the technical solutions in the embodiments of the present disclosure or the prior art, the following will briefly introduce the drawings that need to be used in the description of the embodiments or the prior art. Obviously, the accompanying drawings in the following description These are some embodiments of the present disclosure. For those skilled in the art, other drawings can also be obtained according to these drawings without creative work.
图1为本公开一些实施例提供的放射性药物的运输容器的爆炸结构示意图;FIG. 1 is a schematic diagram of an exploded structure of a radiopharmaceutical transport container provided by some embodiments of the present disclosure;
图2为图1中铅罐的结构示意图,其中铅罐中容置药物;Fig. 2 is a schematic structural view of the lead tank in Fig. 1, wherein medicine is accommodated in the lead tank;
图3为图2中铅罐的截面结构示意图,其中铅罐中容置药瓶。Fig. 3 is a schematic cross-sectional structure diagram of the lead tank in Fig. 2, wherein a medicine bottle is accommodated in the lead tank.
具体实施方式detailed description
为了使本公开的目的、技术方案和优点更加清楚,下面将结合附图对本公开作进一步地详细描述,显然,所描述的实施例仅仅是本公开一部分实施例,而不是全部的实施例。基于本公开中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其它实施例,都属于本公开保护的范围。In order to make the purpose, technical solutions and advantages of the present disclosure clearer, the present disclosure will be further described in detail below in conjunction with the accompanying drawings. Apparently, the described embodiments are only some of the embodiments of the present disclosure, not all of them. Based on the embodiments in the present disclosure, all other embodiments obtained by persons of ordinary skill in the art without creative efforts fall within the protection scope of the present disclosure.
在本公开实施例中使用的术语是仅仅出于描述特定实施例的目的,而非旨在限制本公开。在本公开实施例和所附权利要求书中所使用的单数形式的“一种”、“所述”和“该”也旨在包括多数形式,除非上下文清楚地表示其他含义,“多种”一般包含至少两种。Terms used in the embodiments of the present disclosure are for the purpose of describing specific embodiments only, and are not intended to limit the present disclosure. The singular forms "a", "said" and "the" used in the embodiments of this disclosure and the appended claims are also intended to include plural forms, unless the context clearly indicates otherwise, "a plurality" Generally contain at least two.
应当理解,本文中使用的术语“和/或”仅仅是一种描述关联对象的关联关系,表示可以存在三种关系,例如,A和/或B,可以表示:单独存在A,同时存在A和B,单独存在B这三种情况。另外,本文中字符“/”,一般表示前后关联对象是一种“或”的关系。It should be understood that the term "and/or" used herein is only an association relationship describing associated objects, which means that there may be three relationships, for example, A and/or B, which may mean that A exists alone, and A and B exist simultaneously. B, there are three situations of B alone. In addition, the character "/" in this article generally indicates that the contextual objects are an "or" relationship.
下面结合附图详细说明本公开的可选实施例。Optional embodiments of the present disclosure will be described in detail below in conjunction with the accompanying drawings.
图1为本公开一些实施例提供的放射性药物的运输容器的爆炸结构示意图。图2为图1中铅罐的结构示意图,其中铅罐中容置药物。图3 为图2中铅罐的截面结构示意图,其中铅罐中容置药瓶。本公开一些实施例提供一种放射性药物的运输容器,如图1至图3所示,一种放射性药物的运输容器100包括:药瓶10、铅罐20、吸液海绵30、金属密封罐40、缓冲保护层50以及瓦楞纸箱60。Fig. 1 is a schematic diagram of an exploded structure of a radiopharmaceutical transport container provided by some embodiments of the present disclosure. Fig. 2 is a schematic structural view of the lead tank in Fig. 1, wherein the lead tank accommodates medicines. Fig. 3 is a schematic cross-sectional structure diagram of the lead tank in Fig. 2, wherein a medicine bottle is accommodated in the lead tank. Some embodiments of the present disclosure provide a transport container for radiopharmaceuticals. As shown in FIGS. , the
药瓶10用于为容置放射性药物,放射性药物例如为镥[177Lu]氧奥曲肽注射液,适用于治疗成人不可切除或转移,进行性,高分化(G1和 G2),生长抑素受体阳性胃肠胰神经内分泌肿瘤(GEP-NETs)。镥[177Lu] 氧奥曲肽注射液临床研究疾病进展风险相对于传统疗法降低了79%。The
177Lu由于具有优良的放射性物理特性,在肿瘤治疗领域具有明显优势。其用于临床诊疗时具有如下优点:Due to its excellent radioactive physical properties, 177 Lu has obvious advantages in the field of tumor therapy. It has the following advantages when used in clinical diagnosis and treatment:
(1)177Lu的β射线在小体积肿瘤中有较好的能量沉积,同时又不会发射高能β射线(76%β衰变(Eβ(max)=0.497MeV))对周围健康组织造成高副作用;(1) The β-rays of 177 Lu have good energy deposition in small-volume tumors, and at the same time, they will not emit high-energy β-rays (76% β-decay (E β (max)=0.497MeV)) and cause high damage to surrounding healthy tissues. side effect;
(2)伴随β射线发射的低能γ射线(Eγ=113keV(6.6%),208keV (11%))可以进行SPECT显像,这一性质在现今“精准医疗”、“个性化医疗”、“诊疗一体”为导向的新一代放射性药物开发策略中极为有利。(2) Low-energy γ-rays (E γ = 113keV (6.6%), 208keV (11%) accompanied by β-ray emission can be used for SPECT imaging. This property is used in "precision medicine", "personalized medicine", " It is extremely beneficial in the development strategy of a new generation of radiopharmaceuticals oriented towards the integration of diagnosis and treatment.
(3)在溶液中,Lu以+3氧化态形式存在,易于与N,O形成配位反应,故可以通过双功能化配体与众多载体进行连接。同时Lu没有其他稳定价态,在溶液中难以发生氧化还原反应,可以在各种化学环境中稳定以+3价稳定存在,有助于获得纯度高、化学性质稳定的 Lu标记药物,也可有效避免体内代谢研究过程中177Lu脱靶,造成对其他组织的副作用。(3) In the solution, Lu exists in the +3 oxidation state, which is easy to form a coordination reaction with N, O, so it can be connected to many supports through bifunctional ligands. At the same time, Lu has no other stable valence state, and it is difficult to undergo oxidation-reduction reactions in the solution. It can stably exist in various chemical environments with a +3 valence, which helps to obtain Lu-labeled drugs with high purity and stable chemical properties, and can also be effective. Avoid 177 Lu off-target during in vivo metabolism research, causing side effects on other tissues.
(4)177Lu有合适的半衰期(6.64天),为放射性标记、纯化、质控和运输等繁琐的程序提供了便利。(4) 177 Lu has a suitable half-life (6.64 days), which provides convenience for tedious procedures such as radiolabelling, purification, quality control and transportation.
177Lu毒性分组为中毒的放射性核素。其半衰期约为6.64天,得益于其衰变特点,其衰变的β射线有能量低、射程短、无放射性气溶胶的特点,在辐射防护上,仅做好放射性屏蔽就能达到《放射性物品安全运输规程》中的相关要求。 177Lu Toxicity grouped as poisoned radionuclides. Its half-life is about 6.64 days. Thanks to its decay characteristics, its decayed β-rays have the characteristics of low energy, short range, and no radioactive aerosol. In terms of radiation protection, only good radioactive shielding can achieve the "Radioactive Material Safety Relevant requirements in the Transport Regulations.
药瓶10例如为西林瓶,其例如为采用硼硅玻璃制造的注射剂瓶,其包括药瓶本体以及与药瓶本体匹配的胶塞,胶塞扣合在药瓶本体上可以将容置药瓶本体内的放射性药物密封。The
铅罐20用于容置药瓶10,用于隔绝放射性药物的辐射,避免辐射泄漏造成污染。The
吸液海绵30用于包裹所述铅罐20以吸收外泄液体,即使铅罐以及其容置的药瓶发生破损,流出铅罐的液态的放射性药物也会被吸液海绵吸附,避免液体外泄,符合航空运输的要求。吸液海绵30包括海绵本体31以及海绵盖体32,海绵本体31上设置有第一槽部311,海绵盖体 32上设置有第二槽部,海绵盖体32扣合在海绵本体上时,第一槽部 311与第二槽部对准拼接,两者拼接成槽部,用于容置铅罐20。所述槽部的形状和尺寸与铅罐的形状和尺寸相匹配,基本上刚好容置该铅罐 20,例如铅罐20呈圆柱形,槽部亦称呈圆柱形槽部。例如槽部的尺寸等于或略小于铅罐的尺寸,使得铅罐20放入吸液海绵30的槽部时可以被吸液海绵30包覆加紧,防止铅罐20在吸液海绵30的槽部中晃动。吸液海绵30还起到了稳固铅罐的作用,另外吸液海绵30的弹性性能还可以提供缓冲作用,防止铅罐20发生破损。The liquid-absorbing
金属密封罐40容置由所述吸液海绵包裹的所述铅罐。金属密封罐例如采用马口铁(镀锡铁)等防腐蚀材料制成,其具有良好的密封防腐特性,且价格低廉。即使铅罐以及其容置的药瓶发生破损,金属密封罐 40可以将吸附有放射性药液的吸液海绵密封,防止污染外泄。在一些实施例中,金属密封罐40内部空间的形状与尺寸与吸液海绵30的形状与尺寸相匹配。例如如图1所示,吸液海绵30的形状例如呈圆柱形,金属密封罐40的内部空间亦呈圆柱形。吸液海绵30的尺寸例如等于或略大于金属密封罐40的内部空间的尺寸,使得包裹有铅罐20的吸液海绵30容置在金属密封罐40中时,可以避免包裹有铅罐20的吸液海绵 30在金属密封罐40中晃动,可以稳固铅罐及其中的药瓶。The metal
缓冲保护层50配置为包裹所述金属密封罐40,起到缓冲的作用,例如采用珍珠泡棉材料制成。缓冲保护层50包括保护层本体51以及保护层盖体52,保护层本体51上设置有第三槽部511,例如为非贯通槽部,保护层盖体52上设置有第四槽部521,例如为非贯通槽部,保护层盖体52扣合在保护层本体51上时,第三槽部511与第四槽部521对准拼接,两者拼接成容纳槽部,用于容置金属密封罐40。所述容纳槽部的形状和尺寸与金属密封罐40的形状和尺寸相匹配,基本上刚好容置该金属密封罐40。例如金属密封罐40呈圆柱形,容纳槽部亦称呈圆柱形槽部。例如容纳槽部的尺寸等于或略小于金属密封罐40的尺寸,使得金属密封罐40放入缓冲保护层50的容纳槽部时可以被缓冲保护层 50包覆加紧,防止金属密封罐40在缓冲保护层50的容纳槽部中晃动。缓冲保护层50还起到了稳固铅罐的作用,缓冲保护层50的弹性性能还可以提供缓冲作用,防止金属密封罐40发生破损。The
瓦楞纸箱60配置为容置由所述缓冲保护层50包裹的所述金属密封罐40。瓦楞纸箱60作为运输容器100的最外层包装,具有重量轻,缓冲性好,价格低廉,利于回收等优点。在一些实施例中,瓦楞纸箱60 内部空间的形状与尺寸与缓冲保护层50的形状与尺寸相匹配。例如如图1所示,缓冲保护层50的形状例如呈正方体形,瓦楞纸箱60的内部空间亦呈正方体。缓冲保护层50的尺寸例如等于或略大于瓦楞纸箱60 的内部空间的尺寸,使得包裹有金属密封罐40的缓冲保护层50容置在瓦楞纸箱60中时,可以避免包裹有金属密封罐40的缓冲保护层50在瓦楞纸箱60中晃动,可以稳固金属密封罐40。在一些实施例中,瓦楞纸箱60的外观例如呈正方体型,边长例如为25cm,利于装载搬运。The
在一些实施例中,容置药瓶10后的铅罐20的表面进行热塑封使得所述铅罐20外表面包裹热塑密封膜。通常将放射性药物分装至药瓶并将药瓶容置在铅罐中的工序需要在防辐射的环境,例如防辐射箱中进行,铅罐的外表面难免会沾污少量的放射性污染。为了避免后续运输操作过程中对操作人员造成危害,将自放射性环境中取出的容置有药瓶铅罐采用热塑封的工艺在铅罐外表面形成热塑密封膜,将铅罐20密封包裹,以隔绝铅罐外表面上的放射性沾污。In some embodiments, the surface of the lead can 20 that accommodates the
另外,采用热塑密封膜包括铅罐20,可以使得铅罐的铅罐本体与铅罐盖体封在一起,使得两者不易分离,保证铅罐在运输过程中的密封性。In addition, the lead can 20 is covered with a thermoplastic sealing film, so that the lead can body and the lead can cover can be sealed together so that the two are not easy to separate, ensuring the tightness of the lead can during transportation.
上述实施例中,采用瓦楞纸箱、吸液海绵等配合铅罐及药瓶构成一次性运输容器,在满足放射性防护要求以及航空运输要求的情况下,降低成本。上述的运输容器体积小,有利于装载安全;重量轻,利于航空运输;包装方式简单,可以确保包装质量稳定可靠;一次性使用运输包装材料,避免重复使用运输包装在使用过程中的破损对复用的不安全因素。In the above embodiments, corrugated boxes, liquid-absorbing sponges, etc. are used together with lead cans and medicine bottles to form disposable transport containers, which can reduce costs while meeting the requirements for radioactive protection and air transport. The above-mentioned transport container is small in size, which is conducive to safe loading; light in weight, conducive to air transport; simple in packaging, which can ensure stable and reliable packaging quality; one-time use of transport packaging materials, avoiding the damage of repeated use of transport packaging during use. Unsafe factors used.
在一些实施例中,铅罐的防护厚度由以下方式确定。In some embodiments, the protective thickness of the lead can is determined in the following manner.
辐射防护屏蔽计算公式如下:The formula for calculating radiation protection shielding is as follows:
其中:表示比释动能率;in: Indicates the kerma rate;
A表示放射源活度;A represents the activity of the radioactive source;
Гk表示空气比释动能率常数(1.19×10-18Gy·m2·Bq-1·S-1);Г k represents the air kerma rate constant (1.19×10 -18 Gy·m 2 ·Bq -1 ·S -1 );
r表示运输容器外表面到放射源距离,以边长为25cm的正方体为例,r represents the distance from the outer surface of the transport container to the radioactive source, taking a cube with a side length of 25cm as an example,
r可以取0.125m。r can take 0.125m.
以250mCi的氧奥曲肽注射液(177Lu-DOTATATE)为例Take 250mCi Oxyoctreotide Injection ( 177 Lu-DOTATATE) as an example
由于其中,表示吸收剂量率;because in, Indicates the absorbed dose rate;
其中,H表示当量剂量;辐射权重因子Q=1。Wherein, H represents equivalent dose; radiation weight factor Q=1.
若运输容器外表面剂量控制在0.005mSv/h,则减弱倍数 K=2.54/0.005=508倍,射线能量保守按照0.25MeV计算,0.25MeV铅的半价层厚度为0.88mm,计算lg2(508)为8.9887,乘半价层厚度 0.88mm即得铅屏蔽层厚度约为8mm。同时,再将铅罐包装在次级运输包装中,使得运输容器距离铅罐的距离为10cm,则货包表面的剂量率将远低于0.005mSv/h。If the dose on the outer surface of the transport container is controlled at 0.005mSv/h, then the attenuation factor K=2.54/0.005=508 times, the ray energy is conservatively calculated according to 0.25MeV, the half-valence layer thickness of 0.25MeV lead is 0.88mm, and the calculated lg2(508) is 8.9887, multiplied by the thickness of the half-price layer 0.88mm, the thickness of the lead shielding layer is about 8mm. At the same time, if the lead cans are packed in the secondary transport packaging so that the distance between the transport container and the lead cans is 10cm, the dose rate on the surface of the package will be much lower than 0.005mSv/h.
根据上述计算,最大177Lu活度为250mCi,设计铅罐厚度为9mm,增加冗余量,铅罐置于瓦楞纸箱中心,铅罐表面距离运输容器表面10cm (运输容器表面距离放射源中心12.5cm)。使用Rad Pro calculator辐射防护计算软件计算,运输容器表面剂量率为0.16μSv/h。远低于《放射性物品安全运输规程》中0.005mSv/h<H≤0.5mSv/h的规定。According to the above calculation, the maximum 177 Lu activity is 250mCi, the design lead tank thickness is 9mm, and the redundancy is increased. The lead tank is placed in the center of the corrugated box, and the surface of the lead tank is 10cm away from the surface of the transport container (the distance between the surface of the transport container and the center of the radioactive source is 12.5cm). ). Using Rad Pro calculator radiation protection calculation software to calculate, the surface dose rate of the transport container is 0.16μSv/h. It is far lower than the regulation of 0.005mSv/h<H≤0.5mSv/h in the "Regulations for the Safe Transport of Radioactive Materials".
以下具体介绍铅罐结构,如图2-3所示,所述铅罐20包括铅罐本体21和铅罐盖体22。The structure of the lead tank will be described in detail below. As shown in FIGS. 2-3 , the
铅罐本体21所述铅罐本体内设置有敞口的容置槽211,所述容置槽211包括依次远离所述容置槽底部且依次邻接的第一容置空间2111 以及第二容置空间2112,所述容置槽211配置为容置所述药瓶10的至少一部分。药瓶10例如包括药瓶本体11以及胶塞12。胶塞12例如为丁基胶塞。胶塞12可以扣合在药瓶本体11上实现药瓶10的密封。在一些实施例中,药瓶10还可以包括封装盖,例如为铝盖,将胶塞封装在药瓶本体11上。如图1至图3所示,药瓶本体11的颈部及其以上部分例如容置在第二容置空间2112中,药瓶本体11的颈部以下部分例如容置在第一容置空间2111中。The lead can
铅罐盖体22具有凹槽221,当所述铅罐盖体22扣合在所述铅罐本体21上时,所述容置槽211与所述凹槽221组成容纳部,用于密闭容纳所述药瓶10,所述铅罐盖体22的侧壁的至少一部分容置在所述第二容置空间2112中。即铅罐盖体22的一部分插入容置槽211中,使得铅罐盖体22密闭扣合至铅罐本体21上。The
在一些实施例中,如图2至图3所示,在所述铅罐本体21的轴线 m1的方向上,所述第二容置空间2112的内侧壁随着逐渐靠近所述第一容置空间2111逐渐朝向所述铅罐本体的轴线m1收敛。便于药瓶10进入铅罐本体21中。In some embodiments, as shown in FIG. 2 to FIG. 3 , in the direction of the axis m1 of the
所述铅罐盖体22的侧壁的外表面222包括第一外表面2221,在所述铅罐盖体的轴线m2的方向上,所述第一外表面2221随着逐渐远离所述铅罐盖体顶面逐渐朝向所述铅罐盖体的轴线m2收敛。当所述铅罐盖体22扣合在所述铅罐本体21上时,所述第一外表面2221与所述第二容置空间2112的内侧壁匹配贴合使得铅罐本体21的轴线m1与所述铅罐盖体22的轴线m2共线。如图2至图3所示,第一外表面2221的截面例如为斜面,第二容置空间2112的内侧壁的截面亦为斜面,两者斜度相同,两者的斜度范围例如为tg45°~tg70°。采用该种设置,将铅罐盖体22扣合在铅罐本体21上时,在铅罐盖体22本身自重的作用下,铅罐盖体22可以与铅罐本体21自对准扣合,便于铅罐盖体22与铅罐本体21的密闭扣合。The
在一些实施例中,如图2至图3所示,所述铅罐本体21的侧壁的最大厚度D1小于所述铅罐盖体22的侧壁的最大厚度D2,所述铅罐盖体22的侧壁的内表面与所述第一外表面2221相交处具有圆角。采用该种设计,可以避免所述铅罐本体的侧壁的最大厚度等于所述铅罐盖体的侧壁的最大厚度的情况下,铅罐盖体和铅罐本体自对准扣合时,在铅罐盖体22的侧壁的内表面与所述第一外表面2221相交处形成尖角,导致铅质的尖角处容易破损。In some embodiments, as shown in FIG. 2 to FIG. 3 , the maximum thickness D1 of the side wall of the lead can
具体地,在一些实施例中,所述铅罐盖体22的侧壁的内表面平行于所述铅罐盖体22的轴线m2,所述第一容置空间2111的内侧壁平行于所述铅罐本体21的轴线m1,当所述铅罐盖体22扣合在所述铅罐本体21上时,所述铅罐盖体22的侧壁的内表面相对于所述第一容置空间 2111的内侧壁更加靠近所述铅罐本体的轴线m2。Specifically, in some embodiments, the inner surface of the side wall of the lead can
在一些实施例中,所述铅罐盖体22的侧壁的外表面222还包括第二外表面2222和第三外表面2223,所述第三外表面2223位于所述第二外表面2222与第一外表面2221之间。当所述铅罐盖体22扣合在所述铅罐本体21上时,所述第二外表面2222与所述铅罐本体21的外侧壁共面,所述第三外表面2223与所述铅罐本体21的侧壁顶面匹配贴合。In some embodiments, the
在一些实施例中,第三外表面2223例如垂直于铅罐盖体22的轴线 m2,所述铅罐本体21的侧壁顶面例如垂直于铅罐本体21的轴线m1。In some embodiments, the third
在一些实施例中,所述铅罐的材质为铅锑合金使得所述铅罐可以采用冲压方式制造。具体地,铅锑合金中,锑的含量例如为3%~4%之间,该种含量的铅锑合金的硬度适中,可以采用冲压的方式制造铅罐。相较于相关技术中采用注塑工艺,本公开中的冲压工艺可以降低生成成本,提高生产效率。且采用冲压方式制造的铅罐,还可以避免铅罐的夹渣、气孔和/或缩孔等缺陷。In some embodiments, the material of the lead can is lead antimony alloy so that the lead can can be manufactured by stamping. Specifically, in the lead-antimony alloy, the content of antimony is, for example, between 3% and 4%. The hardness of the lead-antimony alloy with such content is moderate, and lead cans can be manufactured by stamping. Compared with the injection molding process used in the related art, the stamping process in the present disclosure can reduce production cost and improve production efficiency. Moreover, the lead cans manufactured by stamping can also avoid defects such as slag inclusions, air holes and/or shrinkage cavities of the lead cans.
在一些实施例中,所述铅罐的外表面涂覆有防护漆,避免铅直接暴露至操作人员,对操作人员进行保护。In some embodiments, the outer surface of the lead tank is coated with protective paint to avoid direct exposure of lead to operators and protect operators.
本公开一些实施例还提供前述实施例中的所述容器在转移放射性颗粒中的用途,例如是前述实施例中的所述容器在利用双针系统转移放射性颗粒中的用途。Some embodiments of the present disclosure also provide the use of the container in the foregoing embodiments in transferring radioactive particles, for example, the use of the container in the foregoing embodiments in transferring radioactive particles using a double-needle system.
附图中的流程图和框图,图示了按照本公开各种实施例的系统、方法和计算机程序产品的可能实现的体系架构、功能和操作。在这点上,流程图或框图中的每个方框可以代表一个模块、程序段、或代码的一部分,该模块、程序段、或代码的一部分包含一个或多个用于实现规定的逻辑功能的可执行指令。也应当注意,在有些作为替换的实现中,方框中所标注的功能也可以以不同于附图中所标注的顺序发生。例如,两个接连地表示的方框实际上可以基本并行地执行,它们有时也可以按相反的顺序执行,这依所涉及的功能而定。也要注意的是,框图和/或流程图中的每个方框、以及框图和/或流程图中的方框的组合,可以用执行规定的功能或操作的专用的基于硬件的系统来实现,或者可以用专用硬件与计算机指令的组合来实现。The flowchart and block diagrams in the Figures illustrate the architecture, functionality, and operation of possible implementations of systems, methods and computer program products according to various embodiments of the present disclosure. In this regard, each block in a flowchart or block diagram may represent a module, program segment, or portion of code that contains one or more logical functions for implementing specified executable instructions. It should also be noted that, in some alternative implementations, the functions noted in the block may occur out of the order noted in the figures. For example, two blocks shown in succession may, in fact, be executed substantially concurrently, or they may sometimes be executed in the reverse order, depending upon the functionality involved. It should also be noted that each block of the block diagrams and/or flowchart illustrations, and combinations of blocks in the block diagrams and/or flowchart illustrations, can be implemented by a dedicated hardware-based system that performs the specified functions or operations , or may be implemented by a combination of dedicated hardware and computer instructions.
最后应说明的是:本说明书中各个实施例采用递进的方式描述,每个实施例重点说明的都是与其他实施例的不同之处,各个实施例之间相同相似部分互相参见即可。对于实施例公开的系统或装置而言,由于其与实施例公开的方法相对应,所以描述比较简单,相关之处参见方法部分说明即可。Finally, it should be noted that each embodiment in this specification is described in a progressive manner, each embodiment focuses on the difference from other embodiments, and the same and similar parts of each embodiment can be referred to each other. As for the system or device disclosed in the embodiment, since it corresponds to the method disclosed in the embodiment, the description is relatively simple, and for relevant details, please refer to the description of the method part.
以上实施例仅用以说明本公开的技术方案,而非对其限制;尽管参照前述实施例对本公开进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本公开各实施例技术方案的精神和范围。The above embodiments are only used to illustrate the technical solutions of the present disclosure, rather than to limit them; although the present disclosure has been described in detail with reference to the foregoing embodiments, those of ordinary skill in the art should understand that: it can still be described in the foregoing embodiments The recorded technical solutions are modified, or some of the technical features are replaced equivalently; and these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the spirit and scope of the technical solutions of the embodiments of the present disclosure.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202222451405.XU CN218214665U (en) | 2022-09-15 | 2022-09-15 | Lead can and transport container |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202222451405.XU CN218214665U (en) | 2022-09-15 | 2022-09-15 | Lead can and transport container |
Publications (1)
Publication Number | Publication Date |
---|---|
CN218214665U true CN218214665U (en) | 2023-01-03 |
Family
ID=84633712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202222451405.XU Ceased CN218214665U (en) | 2022-09-15 | 2022-09-15 | Lead can and transport container |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN218214665U (en) |
-
2022
- 2022-09-15 CN CN202222451405.XU patent/CN218214665U/en not_active Ceased
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5834788A (en) | Tungsten container for radioactive iodine and the like | |
US8292869B2 (en) | Container for vial of radiopharmaceutical and set for its infusion in a patient or for its transfer elsewhere | |
KR101982893B1 (en) | Liquid container | |
US20070163917A1 (en) | Package and device for simultaneously maintaining low moisture and low oxygen levels | |
CN218214665U (en) | Lead can and transport container | |
CN215555732U (en) | Radiopharmaceutical storage and transportation tank | |
CN115240891A (en) | Transport container for radiopharmaceuticals and uses thereof | |
JP3961588B2 (en) | Radionuclide elution device packaging interior material | |
JPS6245199Y2 (en) | ||
CN206991784U (en) | A kind of neutron holding vessel | |
CN208368181U (en) | A kind of high activity radioactive drugs transport tungsten alloy lead container | |
CN217822088U (en) | Shielding container of radioactive sample bottle | |
CN221708421U (en) | Inner container for radioactive article transportation | |
CN213009141U (en) | Packaging bottle for containing bovine serum or culture medium | |
CN212423870U (en) | Portable medicament box for pharmacy department | |
US11964131B2 (en) | Syringe shield, syringe shipping and administration system, and components therefor | |
Ahmed | Pharmaceutical Considerations in Drug Packaging and Stability | |
HK1077395B (en) | Container for vial of radiopharmaceutical and set for its infusion in a patient or for its transfer elsewhere | |
CN119361201A (en) | A protective container for packaging and transporting radioactive capsules | |
WO2024071355A1 (en) | Liquid-containing combined container, container set, and manufacturing method for liquid-containing container | |
CN203263810U (en) | Sodium bicarbonate injection flexible package container | |
HK1193023B (en) | Liquid container | |
NZ619040B2 (en) | Liquid container | |
JPS5972598U (en) | Spent fuel transportation and storage containers | |
JPS59135398A (en) | Shielding device for transporting cask |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
IW01 | Full invalidation of patent right | ||
IW01 | Full invalidation of patent right |
Decision date of declaring invalidation: 20240626 Decision number of declaring invalidation: 580044 Granted publication date: 20230103 |